Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Male and femal subjects who~* are 18 to 45 years of age, inclusive, on the day of screening;~* have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry;~* are clinically healthy, as determined by medical history and physical examination;~* agree to keep a daily record of symptoms;~* if female and capable of bearing children, have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study.~Exclusion Criteria:~Subjects who~* are at high risk of contracting H5N1 influenza infection (e.g. poultry workers);~* suffer from a significant neurological, cardiac, pulmonary (including asthma), hepatic, rheumatic, autoimmune, hematological or renal disorder;~* are unable to lead an independent life as a result of either physical or mental handicap;~* suffer from any kind of immunodeficiency;~* suffer from a disease or are undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (\>800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs;~* have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré);~* have a history of severe allergic reactions or anaphylaxis;~* have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating;~* have received a blood transfusion or immunoglobulins within 90 days of study entry;~* have donated blood or plasma within 30 days of study entry;~* have received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study;~* have undergone systemic corticoid therapy within 30 days prior to study entry;~* have a functional or surgical asplenia;~* have a known or suspected problem with alcohol or drug abuse;~* were administered an investigational drug within six weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product;~* are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator;~* if female, are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).